Skip to main content

Progress in prevention of perinatal HIV‐1

Buy Article:

$43.00 plus tax (Refund Policy)

The findings of a recent human immunodeficiency (HIV‐1) prevention trial in the USA demonstrated that administration of an antiretriviral drug, zidovudine, to mothers during the prenatal and intrapartum periods, and to their neonates for 6 weeks, resulted in a two‐thirds reduction in risk of perinatal transmission from 25.5% to 8.3%. These results were rapidly disseminated both in the USA and internationally. Since the release of these clinical trial results in the spring of 1994, several observational studies have documented a sharp increase in maternal and neonatal zidovudine use, as well as a significant decrease in perinatal HIV‐1 transmission, with rates of about 8% being observed in non‐clinical trial settings. Internationally, the results have led to the development of a variety of perinatal prevention trials that build on the success of the U.S. perinatal prevention trial but use modified strategies that can feasibly be carried out in developing countries.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Original Article

Affiliations: 1: National Institute of Child Health and Human Development, Bethesda, MD, USA 2: National Institute of Allergy and Infectious Diseases, Bethesda, MD

Publication date: 1997-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more